Does Dr. LUIS CABRERA DE LA MATTA have financial conflicts of interest?

Dr. LUIS CABRERA DE LA MATTA (M.D.) has received a total of $2,411 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $2,411 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LUIS CABRERA DE LA MATTA?

According to CMS Open Payments data, Dr. LUIS CABRERA DE LA MATTA received funding from E.R. SQUIBB & SONS, L.L.C ($445), ASTRAZENECA PHARMACEUTICALS ($435), and JANSSEN PHARMACEUTICALS ($359).

Does Dr. LUIS CABRERA DE LA MATTA receive research grants or speaking fees?

Dr. LUIS CABRERA DE LA MATTA has received $2,411 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LUIS CABRERA DE LA MATTA

M.D.Real-Time Hydrated

Specialty: Family Medicine

Practice Location: SANTURCE, PR 00910

NPI Number: 1538176276

LIFETIME INDUSTRY VALUE

$2,411

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. CABRERA DE LA MATTA is a verified Family Medicine practitioner based in SANTURCE, PR.

Between 2021 and 2025, Dr. CABRERA DE LA MATTA had an overall industry promotional and research financial footprint of $2,411 as recorded in the federal CMS Open Payments database.

$2,411 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. CABRERA DE LA MATTA's primary funding source is E.R. SQUIBB & SONS, L.L.C, which accounts for $445 (representing 18.5% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

E.R. SQUIBB & SONS, L.L.C

Rank 1

$445

18.5%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$435

18%

JANSSEN PHARMACEUTICALS

Rank 3

$359

14.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.